Tyche Industries Ltd.
Snapshot View

View in App

Prices View details

223.65 +3.35 ▲1.5%

02 August 2021, 04:00:00 P.M.
Volume: 20,020

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.tycheindustries.com
Financial Indicators
Market Cap 229.86 Cr.
Earnings per share (EPS) 19.50 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 11.50 Trailing Twelve Months Ending 2021-03
Industry PE 32.66 Trailing Twelve Months Ending 2021-03
Book Value / Share 93.63 Trailing Twelve Months Ending 2021-03
Price to Book Value 2.40 Calculated using Price: 224.25
Dividend Yield 0.45 Period Ending 2020-03
No. of Shares Subscribed 1.03 Cr. 10,250,000 Shares
FaceValue 10
Company Profile

Tyche Industries was incorporated in the year 1998 as Siris Soft. Initially, the company was established as a software company but later on was diversified into the manufacture of fine chemicals.

The company is headquartered in Hyderabad, the Pharmaceutical, Biotech & IT hub of India. Tyche is a leading manufacturer of API's, Intermediates, Nutraceuticals, Fine and Specialty Chemicals. The company focuses on Custom Synthesis/Contract/Toll Manufacturing and Research & Development for API's, Intermediates and Fine & Specialty Chemicals.

An ISO 9001:2000 certified company; Tyche Industries has state-of-the-art manufacturing plants at Kakinada & Tanuku, Andhra Pradesh and a world class Research & Development Centre at Hyderabad, supported by a highly skilled workforce and a strong R&D team of professionals.

The company is deeply committed to quality, safety and environmental regulations. Its manufacturing plants are periodically audited to ensure their effectiveness in meeting tough production targets. Technology is regularly updated and manufacturing techniques are constantly reviewed to ensure they conform to state-of-the-art trends. Regular training programs are held to fine-tune the performance and skill-sets of its employees.

The company’s products include:

  • Active Pharmaceutical Ingredients (API)
  • Intermediates
  • Chiral Intermediates
  • Nutraceuticals
  • Fine Chemicals

The company’s state-of-the-art R&D centre at Hyderabad is equipped with a Kilo lab and sophisticated instrumentation like:

  • HPLC
  • GC with Head space
  • UV/VIS,FITR
  • Digital Polarimeter
  • Auto Titrators, etc.

The company has manufacturing plants at Kakinada and Tanuku with five production blocks covering 18000 sq mts and reactor volume 150000 liters. The plants are capable of handling complex and hazardous reactions within wide range of process parameters. Lot of care has been taken during plant and auxiliary equipment installation considering proper safety aspects.

The manufacturing plants adopt the latest production techniques and comply with stringent guidelines & requirements of good manufacturing practices (cGMP). The company is in the process of having its plants audited by US FDA and WHO GMP.

Equipment

  • Glass Lined Reactors 500 Liters to 5000 liters.
  • Stainless Reactors 500 Liters to 6300 Liters.
  • All Glass Distillation Assemblies.
  • Fractionating Columns.
  • Centrifuges (SS, Rubber Lined).
  • Nutsche Filters.
  • Agitated Nutsche Filter.
  • Rotary Vacuum Driers.
  • Tray Dryers, Blenders, Sifters, Hammer Mills.
  • SS Hydrogenators. 2Kl, 6Kl, with pressure range - 10Kg/cm2.

Utilities

  • Steam Boilers
  • Generators for Alternate Power Supply
  • De-Mineralized Water Plant
  • Chilling Plants at -5°C, -15°C, -30°C
  • Hot Oil Circulation System for temperatures up to 270°C
  • Vacuum up to 1 TORR

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+1.52%
1 Week
+3.33%
1 Month
+7.78%
3 Month
+2.76%
6 Month
+3.06%
1 Year
+21.71%
2 Year
+401.46%
5 Year
+198.20%

Ratios View Details

9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 8.89 16.99 13.43 4.42 5.52 6.59 11.61 12.60 25.55
Return on Capital Employed (%) 12.60 21.85 17.83 7.40 5.22 11.53 17.56 17.36 33.94
Return on Assets (%) 5.28 8.59 6.81 2.80 3.75 4.79 9.18 10.16 20.82

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 33 39 44 44 46 48 53 60 77
Non Curr. Liab. 3 3 4 2 2 3 3 3 3
Curr. Liab. 18 46 26 18 20 10 10 11 15
Minority Int.
Equity & Liab. 54 88 74 64 67 61 67 74 95
Non Curr. Assets 23 29 34 31 31 29 22 21 20
Curr. Assets 30 59 40 33 36 32 45 53 75
Misc. Exp. not W/O
Total Assets 54 88 74 64 67 61 67 74 95

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 49 78 104 64 54 43 52 54 74
Other Income 0 1 0 0 2 2 2 3 4
Total Income 50 79 105 64 56 45 53 56 77
Total Expenditure -43 -68 -94 -57 -51 -37 -43 -45 -52
PBIDT 7 11 11 7 5 8 11 12 25
Interest -1 -1 -1 -1 0 0 0
Depreciation -1 -1 -1 -3 -2 -2 -2 -2 -2
Taxation -1 -3 -3 -1 0 -3 -3 -3 -6
Exceptional Items 0
PAT 3 6 6 2 2 3 6 7 18

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 2 3 9 2 12 11 5 4 14
Cash Fr. Inv. -2 -6 -6 -1 -1 1 6 1 2
Cash Fr. Finan. -3 2 0 -3 2 -11 -1 0 -1
Net Change -2 -1 3 -2 12 1 11 4 15
Cash & Cash Eqvt 2 1 3 1 14 15 25 29 45

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 61.97 61.97 61.97 61.97 61.97 61.98 61.98 61.97 61.97
Public 38.03 38.03 38.03 38.03 38.03 38.02 38.02 38.03 38.03
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00

Announcements View Details

Wed, 28 Jul 2021
Board Meeting Intimation for Approval Of Un-Audited Financial Results Of The Company For The Quarter Ended On 30Th June 2021.
TYCHE INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2021 inter alia to consider and approve Un-Audited Financial Results of the Company for the quarter ended on 30th June 2021.
Limited Review Report of the Statutory Auditors of the Company on the Un-Audited Financial Results for the quarter ended on 30th June 2021
Thu, 15 Jul 2021
Shareholding for the Period Ended June 30 2021
Tyche Industries Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Wed, 07 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- Satya Ranjan Jena
Designation :- Company Secretary and Compliance Officer

Technical Scans View Details

Mon, 02 Aug 2021
High Delivery Percentage High Delivery Percentage
Higher Delivery Quantity Higher Delivery Quantity
Higher Delivery Quantity and Percentage Higher Delivery Quantity and Percentage
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,816.50 774.45 +0.1%
Divi's Laboratories Ltd. 130,822.92 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. 78,219.21 4,701.80 -0.2%
Cipla Ltd. 74,356.30 921.80 +0.2%
Cadila Healthcare Ltd. 60,574.85 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. 58,218.41 4,049.00 +0.4%
Piramal Enterprises Ltd. 56,317.82 2,480.15 +7.0%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 30.95 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 65.93 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.02 4,701.80 -0.2%
Cipla Ltd. Consolidated 2021-03 30.92 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 28.39 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 387.19 4,049.00 +0.4%
Piramal Enterprises Ltd. Consolidated 2021-03 42.27 2,480.15 +7.0%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.88 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 14.08 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.37 4,701.80 -0.2%
Cipla Ltd. Consolidated 2021-03 4.06 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 4.66 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.67 4,049.00 +0.4%
Piramal Enterprises Ltd. Consolidated 2021-03 1.65 2,480.15 +7.0%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,049.00 +0.4%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,480.15 +7.0%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,049.00 +0.4%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,480.15 +7.0%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,049.00 +0.4%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,480.15 +7.0%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,049.00 +0.4%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,480.15 +7.0%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,049.00 +0.4%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,480.15 +7.0%